Figure 5 | Scientific Reports

Figure 5

From: Sphingomyelin nanosystems loaded with uroguanylin and etoposide for treating metastatic colorectal cancer

Figure 5

Graphical representation of (A) in vitro treatments evaluated in this work (UroGm-SNs, Etp-SNs and the combination UroGm-Etp-SNs) all at the same concentration of the active drugs (500 nM Etp and 50 nM UroGm). (B) In vivo antitumor effect in terms of relative tumor volume growth and evaluation of mice body weight. Data presented for control mice and UroGm-Etp-SNs treated mice (n = 6). P values: ****p < 0.0001, **p between 0.001 and 0.01 and *p < 0.05.

Back to article page